Cadrenal Therapeutics, Inc.
New Filing
CIK: 0001937993·Biotechnology·DELAWARE·Filed: Dec 31, 2025
Total Offering
$4,396,329
Amount Sold
$4,396,329
Investors
4
First Sale
Dec 16, 2025
Offering Details
- Type
- Option to Acquire, Security to be Acquired
- Exemptions
- Rule 506(b)
Related Persons
| Name | Role |
|---|---|
| QUANG X. PHAM | Executive Officer, Director |
| MATTHEW K. SZOT | Executive Officer |
| JEFFREY COLE | Executive Officer |
| JAMES J. FERGUSON | Executive Officer |
| STEVEN ZELENKOFSKE | Director |
| GLYNN WILSON | Director |
| JOHN R. MURPHY | Director |
| LEE S. GOLDEN | Director |
Company
SEC Filing
0001213900-25-127129
View on SEC EDGARWant deeper insights?
Sign up for free to search all filings, track companies, and set up alerts.
Sign Up Free